



November 28, 2017

Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

BURLINGTON, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in an analyst-led fireside chat at the Evercore ISI Biopharma Catalyst/Deep Dive Conference in Boston on Thursday, November 30, 2017, at 11:20 am ET.

To access the live webcast and subsequent archived recording of the presentation, please visit the Flexion website at <http://ir.flexiontherapeutics.com/>.

About Flexion Therapeutics

Flexion Therapeutics (Nasdaq:FLXN) is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of the *Boston Business Journal's* 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by *The Boston Globe*.

Corporate Contact:

Scott Young
Sr. Director, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com